Protalix BioTherapeutics, Inc.
PLX
$1.93
$0.021.05%
AMEX
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -5.50M | 2.36M | 164.00K | -3.62M | 6.49M |
| Total Depreciation and Amortization | 387.00K | 372.00K | 360.00K | 346.00K | 334.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 1.37M | 677.00K | 1.14M | 55.00K | 610.00K |
| Change in Net Operating Assets | 5.78M | -7.14M | -6.90M | -1.84M | -3.45M |
| Cash from Operations | 2.03M | -3.73M | -5.23M | -5.06M | 3.99M |
| Capital Expenditure | -403.00K | -498.00K | -431.00K | -306.00K | -425.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | 0.00 |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -709.00K | -6.00K | -7.00K | -6.00K | -14.90M |
| Cash from Investing | -1.11M | -504.00K | -438.00K | -312.00K | -15.32M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | 0.00 |
| Issuance of Common Stock | 146.00K | 0.00 | 4.10M | 5.08M | 3.63M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 146.00K | 0.00 | 4.10M | 5.08M | 3.63M |
| Foreign Exchange rate Adjustments | -31.00K | -12.00K | 4.00K | -8.00K | 54.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 1.03M | -4.25M | -1.56M | -302.00K | -7.65M |